The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
If you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. We will perform experiments on your blood cells.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Basic Science
|Official Title:||The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils|
- Basophil histamine release [ Time Frame: After 4 weeks treatment ] [ Designated as safety issue: No ]
|Study Start Date:||June 2007|
|Estimated Study Completion Date:||November 2012|
|Estimated Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Placebo Comparator: 1
Saline injection to match active
Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
Other Name: Saline
Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
150 to 375 mg is administered SC every 2 or 4 weeks
Other Name: Omalizumab, rhumab-E25
Adult ragweed allergic subjects will have blood drawn. Basophils will be enriched and stimulated with allergen and controls. Supernatants from these stimulations will be assayed for cytokines and histamine.
|United States, Nebraska|
|Omaha, Nebraska, United States, 68131|
|Principal Investigator:||Robert G Townley, MD||Creighton University|